Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.

Nature reviews. Cancer - 1 Feb 2024

Riaud Melody, Maxwell Jennifer, Soria-Bretones Isabel, Dankner Matthew, Li Meredith, Rose April A N

Abstract excerpt

The RAF family of kinases includes key activators of the pro-tumourigenic mitogen-activated protein kinase pathway. Hyperactivation of RAF proteins, particularly BRAF and CRAF, drives tumour progression and drug resistance in many types of cancer. Although BRAF is the most studied RAF protein, partially owing to its high mutation incidence in melanoma, the role of CRAF in tumourigenesis and drug resistance is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Melanoma
Share to Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Phosphorylation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 38195917
DOI: 10.1038/s41568-023-00650-x

Genes

BRAF
RAF1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.PMID 38195917Read ↗

Targeting CRAF kinase in anti-cancer therapy: progress and opportunities.Semantic proximity Read ↗

CRAF mutations in lung cancer can be oncogenic and predict sensitivity to combined type II RAF and MEK inhibitionSemantic proximity Read ↗

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.Semantic proximity Read ↗

RAF1 S257L/S259F hotspot mutations: functional characterization and intrinsic resistance to the RAS(ON) inhibitor daraxonrasib in melanoma.Semantic proximity Read ↗

B-Raf mutation: a key player in molecular biology of cancer.Semantic proximity Read ↗

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.Semantic proximity Read ↗

CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation.Semantic proximity Read ↗

Aberrant B-Raf signaling in human cancer -- 10 years from bench to bedside.Semantic proximity Read ↗

Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.Semantic proximity Read ↗

In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.Semantic proximity Read ↗

The RAF cysteine-rich domain: Structure, function, and role in disease.Semantic proximity Read ↗

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.